SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Applied Digital Corp. is a technology company, which engages in the provision of development and operation of data centers which provide computing power. It operates through the Data Center Hosting Business and HPC Hosting Business segments. The Data Center Hosting Business segment provides energized infrastructure services to crypto mining customers. The HPC Hosting Business segment focuses on the designing, constructing, and operating data centers tailored to support high power density applications like HPC and AI. The company was founded by Wesley Carl Cummins and Jason Zhang in May 2001 and is headquartered in Dallas, TX.

Applied Digital Corporation

APLD is trending as investors debate the stock's valuation amidst broader AI sector concerns and recent financing announcements. Community discussions revolve around the company's long-term potential as an AI infrastructure provider versus short-term market pressures, including debt and dilution. Despite positive updates and contract wins, the stock faces headwinds from AI bubble fears and overall market volatility.

Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY.

Anavex Life Sciences Corporation

Anavex Life Sciences Corp

AVXL is trending as the community anticipates a decision from the European Medicines Agency (EMA) regarding its Alzheimer's treatment, blarcamesine, following a recent oral hearing. Discussions revolve around potential outcomes, ranging from full approval to conditional approval or rejection, and the implications for patients and investors. Some traders are closely watching the stock, noting the high short interest and the potential for a short squeeze if the news is positive.

TSS, Inc. engages in the provision of comprehensive services for the planning, design, development and maintenance of mission-critical facilities and information infrastructure as well as integration services. It operates through the Facilities and Systems Integration Services business segments. The Facilities segment consists of the design, project management, and maintenance of data center and mission-critical business operations. The Systems Integration segment integrates information technology equipment for original equipment manufacturer vendors and customers to be used inside data center environments, including modular data centers. The company was founded by Gerard J. Gallagher on December 20, 2004 and is headquartered in Round Rock, TX.

TSS Inc

TSSI is trending due to a significant after-hours drop following disappointing earnings, with revenue down 40%. The community is debating the impact of this miss, with some concerned about the company's reliance on Dell and others suggesting it's an overreaction, highlighting the company's growth potential and backlog with institutions loading up shares. Discussions revolve around whether this dip is a buying opportunity or a sign of deeper issues within the company.

Ripple is the catchall name for the cryptocurrency platform, the transactional protocol for which is actually XRP, in the same fashion as Ethereum is the name for the platform that facilitates trades in Ether. Like other cryptocurrencies, Ripple is built atop the idea of a distributed ledger network which requires various parties to participate in validating transactions, rather than any singular centralized authority. That facilitates transactions all over the world, and transfer fees are far cheaper than the likes of bitcoin. Unlike other cryptocurrencies, XRP transfers are effectively immediate, requiring no typical confirmation time.  Ripple was originally founded by a single company, Ripple Labs, and continues to be backed by it, rather than the larger network of developers that continue bitcoin’s development. It also doesn’t have a fluctuating amount of its currency in existence. Where bitcoin has a continually growing pool with an eventual maximum, and Ethereum theoretically has no limit, Ripple was created with all of its 100 billion XRP tokens right out of the gate. That number is maintained with no mining and most of the tokens are owned and held by Ripple Labs itself — around 60 billion at the latest count.  Even at the recently reduced value of around half a dollar per XRP, that means Ripple Labs is currently sitting on around $20 billion worth of the cryptocurrency (note: Ripple’s price crashed hard recently, and may be worth far less than $60 billion by time you read this). It holds 55 billion XRP in an escrow account, which allows it to sell up to a billion per month if it so chooses in order to fund new projects and acquisitions. Selling such an amount would likely have a drastic effect on the cryptocurrency’s value, and isn’t something Ripple Labs plans to do anytime soon.  In actuality, Ripple Labs is looking to leverage the technology behind XRP to allow for faster banking transactions around the world. While Bitcoin and other cryptocurrencies are built on the idea of separating financial transactions from the financial organizations of traditional currencies, Ripple is almost the opposite in every sense.  XRP by Ripple price can be found on this page alongside the market capitalization and additional stats.

Ripple

XRP is trending amid excitement surrounding the launch of its first spot ETF, though some traders express concern about immediate price impact and broader market conditions. Community discussions revolve around the potential for institutional investment and the impact of ETF inflows, while some skepticism and frustration remain due to past price disappointments. Overall, the community is weighing the potential long-term benefits of the ETF against short-term market volatility.

Red Cat Holdings, Inc. provides products, services and solutions to the drone industry. It also engages in the provision of distributed data storage, analytics and services for the drone industry.The firm product include Dronebox, which is a blockchain technology that records, stores and analyzes flight data and information from a drone. It operates through the Enterprise Segment. The Enterprise Segment will focus on developing a hardware enabled software platform of services and solutions to government and commercial enterprises and the military. The company was founded by Jeffrey M. Thompson in February 1984 and is headquartered in San Juan, Puerto Rico.

Red Cat Holdings Inc

Red Cat Holdings is trending due to concerns about lowered FY2025 sales guidance, despite a large increase in Q3 revenue, leading to questions about management's credibility and future performance; the community is actively debating the impact of the guidance cut, comparing RCAT to competitors like ONDS, and speculating on potential catalysts like government contracts and defense spending bills in 2026. The stock's volatility and the drone sector's reliance on government contracts are also contributing to the ongoing conversation.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeave is trending as the stock experiences a significant pullback, sparking debates about its valuation and reliance on Nvidia. The community is weighing potential bounce-back opportunities against concerns of a deeper correction in the AI sector. Discussions also involve comparing CoreWeave to competitors and scrutinizing analyst ratings amid the stock's recent volatility.

UnitedHealth Group, Inc. engages in the provision of health care coverage, software, and data consultancy services. It operates through the following segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment utilizes Optum's capabilities to help coordinate patient care, improve affordability of medical care, analyze cost trends, manage pharmacy benefits, work with care providers more effectively, and create a simpler consumer experience. The OptumHealth segment provides health and wellness care, serving the broad health care marketplace including payers, care providers, employers, government, life sciences companies, and consumers. The OptumInsight segment focuses on data and analytics, technology, and information to help major participants in the healthcare industry. The OptumRx segment offers pharmacy care services. The company was founded by Richard T. Burke in January 1977 and is headquartered in Eden Prairie, MN.

Unitedhealth Group Inc

UNH is trending as investors digest mixed signals, including potential impacts from ACA subsidy discussions and upcoming 13F filings that may reveal institutional positions, particularly Berkshire Hathaway's. Community debates center around the stock's short-term direction and long-term value, with some pointing to technical indicators suggesting oversold conditions and potential for a rebound, while others highlight broader concerns about healthcare industry shifts. The stock's reaction to both Trump's comments on insurers and potential government actions are being closely watched.

For every 1 sol in fees 3.3k bags are removed from the ocean. The great unbagging begins.  90% fees go directly to @TheOceanCleanup

Unbagging The Ocean

Unbagging The Ocean is trending as community members promote the coin as a fun, speculative play amidst broader market volatility. The project's mission to save the ocean is also resonating with some investors, while others are more skeptical of the coin's utility.

Applied Materials, Inc. provides manufacturing equipment, services and software to the semiconductor, display and related industries. It operates through the following segments: Semiconductor Systems, Applied Global Services, and Display. The Semiconductor Systems segment includes semiconductor capital equipment for etch, rapid thermal processing, deposition, chemical mechanical planarization, metrology and inspection, wafer packaging, and ion implantation. The Applied Global Services segment provides solutions to optimize equipment, performance, and productivity. The Display segment offers products for manufacturing liquid crystal displays, organic light-emitting diodes, equipment upgrades, and other display technologies for TVs, monitors, laptops, personal computers, smart phones, and other consumer-oriented devices. The company was founded on November 10, 1967 and is headquartered in Santa Clara, CA.

Applied Materials Inc.

Applied Materials is trending due to a significant after-hours drop following earnings, driven by weaker-than-expected guidance and concerns about demand in China. The community is debating whether this presents a buying opportunity or signals deeper issues within the semiconductor equipment sector, particularly regarding exposure to mature nodes and potential tariff impacts. Analysts are divided, with downgrades highlighting near-term headwinds, while others maintain a bullish long-term outlook.

Paysafe Ltd. provides online payment solutions. The firm operates through the following segments: Merchant Solutions and Digital Wallet. The Merchant Solutions business segment focuses on card not present and card present solutions for small to medium size business merchants. The Digital Wallet business segment provides wallet based online payment solutions through its Skrill, eCash solutions and NETELLER brands. The company was founded in 1996 and is headquartered in London, the United Kingdom.

Paysafe Limited

Paysafe Ltd

Paysafe is trending due to negative sentiment surrounding its performance, with community members expressing frustration over missed earnings expectations and a declining stock price. Discussions include concerns about management's credibility and strategic direction, as well as comparisons to other companies in the payment processing sector. Some investors speculate about potential buyback programs or the possibility of the company being taken private.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Merck reportedly edged out another bidder in late-stage talks that could lead to a deal announcement as soon as Friday.</li><li>Cidara’s CD388 flu antibody, now in phase 3 trials with FDA breakthrough status, has driven significant takeover interest.</li><li>Retail traders debated whether the move signals a full buyout or a milestone-based deal structure.</li></ul>Cidara Therapeutics’ shares surged 42% after hours on Thursday following reports that Merck is close to acquiring the biotech in a deal that could be announced as soon as Friday.&nbsp;The negotiations reportedly extended late into Thursday as Merck competed with another pharmaceutical group before the seller ultimately favored its offer. The deal is expected to value Cidara above its roughly $3.3 billion market capitalization, though the final price has apparently not been set. Any agreement is likely to include upfront cash and milestone-based payments tied to clinical progress, according to a&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.ft.com/content/743e1962-3dd1-4785-a20b-4b097e5514ae">report</a> by Financial Times.<h2 class="st-heading-2">Big Pharma Races To Rebuild Pipelines</h2>A potential takeover would mark Merck’s latest move to fortify its drug portfolio before Keytruda, its $25 billion-per-year cancer therapy, loses patent protection in 2028. The company agreed in July to buy respiratory drug developer Verona Pharma for $10 billion as part of a broader effort to maintain revenue momentum. The demand for Cidara comes after another big-name auction last week, when&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/novo-nordisk-loses-metsera-bidding-war-to-pfizer-but-retail-traders-aren-t-losing-faith/cLPcRJWREci">Pfizer narrowly won a race against Novo Nordisk</a> for obesity biotech Metsera in a deal worth as much as $10 billion.<h2 class="st-heading-2">Biotech Sector Heats Up As M&amp;A Wave Accelerates</h2>The race for Cidara is unfolding amid a surge in biotechnology dealmaking.&nbsp;<a href="https://stocktwits.com/symbol/XBI">The XBI biotech index</a> has gained over 40% in the past six months as investors bet on a return of acquisitions by big drugmakers looking to add next-generation therapies to their pipelines. The scramble reflects rising urgency across the sector as companies face major revenue losses once key products lose exclusivity.<h2 class="st-heading-2">Cidara’s Lead Flu Antibody Drives Takeover Expectations</h2>Cidara’s value surge is tied to its lead program, CD388, a long-acting antibody intended to protect against the two most common strains of influenza. The treatment is being evaluated in phase 3 trials among immunosuppressed patients who cannot receive vaccines, as well as healthy adults over 65. Over 6,000 patients are expected to be enrolled in the studies worldwide by the end of the month. CD388 has been granted an&nbsp;FDA breakthrough designation, which could accelerate regulatory approval. Cidara’s shares have quadrupled since July, driven by strong clinical data and takeover speculation that have fueled investor expectations.<h2 class="st-heading-2">Stocktwits Buzz Highlights Takeover Speculation</h2>On Stocktwits, retail sentiment was ‘extremely bullish’ for Cidara and ‘bullish’ for Merck, with both stocks seeing ‘high’ message volume.One user reacted to the report by saying, “sounds like $MRK going in for the kill.”<stembedurl>https://stocktwits.com/JFais/message/636148828</stembedurl>Another user questioned the structure of the potential deal, writing, “It makes me wonder if it is an actual buyout or an investment in the company for rights to their drug? It mentions the possibility of upfront cash plus milestone payments.... hopefully it is a buyout above the current $150 AH price.”<stembedurl>https://stocktwits.com/PooPooPewPew/message/636148400</stembedurl>While&nbsp;<a href="https://stocktwits.com/symbol/CDTX">Cidara’s stock</a> has surged 446% so far in 2025,&nbsp;<a href="https://stocktwits.com/symbol/MRK">Merk’s stock</a> has risen 18% over the same period.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Cidara Therapeutics logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Cidara Therapeutics Stock Soars 42% After-Hours On Merck Buyout Buzz — Retail Traders Eye A Potential Blowout Premium

Merck reportedly edged out another bidder in late-stage talks that could lead to a deal announcement as soon as Friday.

Equity

Cidara Therapeutics Shares Surge In After-Hours On Report Of Nearing Merck Deal

(RTTNews) - Merck & Co. Inc. (MRK) is nearing a deal to acquire Cidara Therapeutics (CDTX), a biotechnology company developing a long-acting antibody treatment for influenza, the Financial Times...

Cidara Therapeutics (NASDAQ:CDTX) Price Target Raised to $145.00 at Royal Bank Of Canada

Royal Bank Of Canada raised their target price on Cidara Therapeutics from $137.00 to $145.00 and gave the company an "outperform" rating in a research report on Friday...

Cidara Therapeutics (NASDAQ:CDTX) Cut to Sell at Wall Street Zen

Wall Street Zen lowered shares of Cidara Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday...

CDTX Stock Up on FDA's Breakthrough Therapy Tag for CD388 in Influenza

Cidara Therapeutics wins FDA Breakthrough Therapy tag for CD388 for the prevention of seasonal influenza. Stock rises.

Cidara Therapeutics, Inc. (CDTX) on Thursday said that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for its drug CD388 for the prevention of influenza A and B in adults and adolescents who are at higher risk of disease-related complications.The new designation is in addition to the Fast Track designation granted to the drug by the agency in June 2023. CEO Jeffrey Stein said that the designations underscore the importance of the drug as a potential new non-vaccine prophylactic for seasonal influenza.“Individuals who have chronic medical conditions, advanced age, or are immune compromised may not be adequately protected by current vaccines, leaving them at higher risk for infection and complications from flu. As a long-acting prophylactic drug, CD388’s activity does not rely on an immune response, making it a potential prevention option for high-risk individuals as well as those for whom vaccines are contraindicated,” he <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/10/09/3164062/0/en/Cidara-Therapeutics-Receives-U-S-FDA-Breakthrough-Therapy-Designation-for-CD388-in-Seasonal-Influenza-Prevention.html">added</a>.The Breakthrough Therapy designation was awarded to the drug based on the results of a study in which CD388 provided statistically significant prevention of seasonal influenza in healthy unvaccinated adults aged 18-64. The company is now looking toward advancing the drug through its ongoing late-stage trial.The Breakthrough Therapy designation is intended to expedite the review of medicines that treat a serious or life-threatening condition. Benefits of the designation include eligibility for priority review and the FDA’s organizational commitment to involving senior management to guide the company on the most efficient route to approval, the company noted.Shares of the company rose 8% at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/CDTX">CDTX stock</a> jumped from ‘bearish’ to ‘neutral’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.<figure class="image"><img style="aspect-ratio:1360/118;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_09_at_12_16_14_PM_png_11f3dc4644.webp" alt="CDTX's Sentiment Meter and Message Volume as of 12:16 p.m. ET on Oct. 09, 2025 | Source: Stocktwits" width="1360" height="118"><figcaption>CDTX's Sentiment Meter and Message Volume as of 12:16 p.m. ET on Oct. 09, 2025 | Source: Stocktwits</figcaption></figure>H.C. Wainwright analyst Sara Nik subsequently raised the firm’s price target on Cidara Therapeutics to $150 from $110 while keeping a ‘Buy’ rating on the shares. The new price target implies a potential upside of over 52% from the stock’s closing price on Wednesday.CDTX stock nearly quadrupled in value this year.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/lyft-partners-with-tensor-to-deploy-hundreds-of-avs-on-its-platform/ch67uQtR3KC">Lyft Partners With Tensor To Deploy Hundreds Of AVs On Its Platform</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Cidara Therapeutics Granted FDA Breakthrough Therapy Designation For Flu-Preventing Antiviral

The Breakthrough Therapy designation was awarded to the drug based on the results of a study in which CD388 provided statistically significant prevention of seasonal influenza in healthy unvaccinated adults aged 18-64.

CDTX Stock Soars 218% YTD on Positive Updates From Influenza Program

Cidara Therapeutics' shares surge 218% this year after its flu candidate CD388 hits key mid-stage study goals and advances into pivotal testing.

U.S. equities declined in Wednesday’s afternoon trade as investors cautiously await the release of key economic data this week, including the third estimate of gross domestic product (GDP) for the second quarter (Q2) on Thursday, and the personal consumption expenditures (PCE) price index on Friday.The&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF</a> (SPY), which mirrors the S&amp;P 500 index, was down 0.39% at the time of writing, while the&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust</a> (QQQ), which mirrors the Nasdaq, fell 0.6%. The&nbsp;<a href="https://stocktwits.com/symbol/DIA">SPDR Dow Jones Industrial Average ETF Trust</a> (DIA), which tracks the Dow Jones Industrial Average, declined 0.31%.Here are the top stocks making the biggest moves in Wednesday’s midday trade:<a href="https://stocktwits.com/symbol/LAC">Lithium Americas Corp. (LAC)</a>Lithium Americas’ shares skyrocketed over 96% in Wednesday’s afternoon trade after the company&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/lithium-americas-stock-surge-captures-wall-street-attention-here-is-why/chD1GtUR33g">confirmed</a> that it is in talks with the U.S. Department of Energy and its joint venture partner General Motors Co. (GM) in the Thacker Pass lithium project over the renegotiation of a $2.26 billion Energy Department loan.<a href="https://stocktwits.com/symbol/LAC">LAC stock</a> is up 101% year-to-date.<a href="https://stocktwits.com/symbol/BABA">Alibaba Group Holdings (BABA)</a>Alibaba’s U.S.-listed shares surged more than 9% in Wednesday’s afternoon session after the company announced plans to boost investment in artificial intelligence by over $53 billion.<a href="https://stocktwits.com/symbol/BABA">BABA stock</a> is up 110% year-to-date.<a href="https://stocktwits.com/symbol/QURE">uniQure NV (QURE)</a>uniQure shares soared more than 260% on Wednesday afternoon after the company&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/uniqure-stock-rises-pre-market-after-investigational-huntingtons-disease-drug-slows-disease-in-trial/chD1GAOR33X">said</a> that a high dose of its experimental gene therapy AMT-130 demonstrated a statistically significant slowing of disease progression in Huntington’s disease in an early-to-mid stage trial.<a href="https://stocktwits.com/symbol/QURE">QURE stock</a> is up 178% year-to-date.<a href="https://stocktwits.com/symbol/IREN">IREN (IREN)</a>IREN shares surged over 16% on Wednesday afternoon following an&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/iren-stock-surged-15-percent-today-here-is-a-price-target-update/chD1drjR33t">announcement</a> by the company that it has doubled its AI Cloud capacity to a total of 23,000 GPUs (graphic processing units), supporting the company’s goal of achieving more than $500 million in annualized AI Cloud revenue by the first quarter of 2026.<a href="https://stocktwits.com/symbol/IREN">IREN stock</a> is up 393% year-to-date.<a href="https://stocktwits.com/symbol/CDTX">Cidara Therapeutics Inc. (CDTX)</a>Cidara shares gained over 21% in Wednesday’s afternoon trade after the company announced plans for a Phase 3 study for CD388, a non-vaccine preventative of seasonal influenza.<a href="https://stocktwits.com/symbol/CDTX">CDTX stock</a> is up 232% year-to-date.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/scott-bessent-surprised-by-strength-of-fed-chair-candidates/chD1cDJR33N">Scott Bessent Says He’s Surprised By Strength Of Fed Chair Candidates: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

A bull statue and a bear statue stand outside the Frankfurt Stock Exchange on April 7, 2025 in Frankfurt, Germany

Lithium Americas, Alibaba, uniQure, IREN, Cidara: Stocks Making The Biggest Moves Today

Lithium Americas’ shares skyrocketed over 96% in Wednesday’s afternoon trade after the firm confirmed that it is in talks with the Energy Department and GM over the $2.6 billion Thacker Pass project loan.

Cidara Therapeutics (CDTX) Upgraded to Buy: Here's What You Should Know

Cidara Therapeutics (CDTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Has Black Diamond Therapeutics (BDTX) Outpaced Other Medical Stocks This Year?

Here is how Black Diamond (BDTX) and Cidara Therapeutics (CDTX) have performed compared to their sector so far this year.

Cidara Therapeutics, Inc. engages in developing targeted immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases. Its platform, Cloudbreak, enables development of novel drug-Fc conjugates (DFCs) that inhibit specific disease targets while simultaneously engaging the immune system. The company was founded by Kevin M. Forrest, Kevin J. Judice, and H. Shaw Warren in December 2012 and is headquartered in San Diego, CA.

Cidara Therapeutics Inc

$IONQ

$RGTI

$QBTS

$QUBT

Are you buying the dip on any of these quantum stocks? 
 
If no, drop a comment.

Stocktwits

Stocktwits Polls

Cidara Therapeutics is trending amid speculation of a potential buyout by Merck after positive Phase 3 data, with community members discussing the possibility of a bidding war and high premium. The company's flu antibody, CD388, is viewed as a key asset, potentially preparing Merck for its Keytruda patent expiration. Some traders are setting high price targets while others highlight the potential for this to be a long-term hold, due to the increased market value and future opportunities.

Current Price	$150.00
Prev Close	$107.12
Open	$106.15
Dividend Yield	0.00%
50-Day Moving Average	$92.51
Beta	0.63
Avg. Volume	973,658.52
PE Ratio	-8.99

52-Week High	$121.21
52-Week Low	$13.90
Market Capitalization	$3.37B
EPS (Annual)	-$26.46
Price to Book	7.36
Revenue Per Employee	$33,552.63
Enterprise Value/EBITDA	N/A

CDTX
Cidara Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest CDTX News

CDTXCidara Therapeutics Inc